Pancreatic Cancer Research

ResearcherSecond Military Medical UniversityActive in the last 2 years

Bin Song

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5917-1977; OpenAlex author ID A5050030395. Sources: OpenAlex.

Their work

Papers
13 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
56
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 2 papers · 2015: 3 papers · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 3 papers

Papers 13

  1. Pathogenic germline variants in Chinese pancreatic adenocarcinoma patients. Co-author DOI 10.1038/s41467-025-57520-3↗
  2. Senescence-driven molecular subtyping in pancreatic cancer: a multi-omics framework for precision medicine. Co-author DOI 10.1186/s12885-025-15341-z↗
  3. Identification of key genes in pancreatic ductal adenocarcinoma with biologically informed deep neural network. Last author DOI 10.21037/jgo-2025-218↗
  4. Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41591-023-02790-x↗
  5. Morphomolecular staging to improve stratification of patients with node-negative pancreatic cancer. Co-author DOI 10.1093/bjs/znac457↗
  6. Blood small extracellular vesicles derived miRNAs to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. Co-author DOI 10.1002/ctm2.520↗
  7. OCIAD1 promoted pancreatic ductal adenocarcinoma migration by regulating ATM. Co-author DOI 10.1016/j.pan.2019.01.009↗
  8. MiR-940 inhibited pancreatic ductal adenocarcinoma growth by targeting MyD88. Co-author DOI 10.1159/000373941↗
  9. miR-429 determines poor outcome and inhibits pancreatic ductal adenocarcinoma growth by targeting TBK1. Co-author DOI 10.1159/000373995↗
  10. Downregulation of ASPP2 in pancreatic cancer cells contributes to increased resistance to gemcitabine through autophagy activation. Co-author DOI 10.1186/s12943-015-0447-5↗
  11. miR-208-induced epithelial to mesenchymal transition of pancreatic cancer cells promotes cell metastasis and invasion. Co-author DOI 10.1007/s12013-013-9805-3↗
  12. miR-545 inhibited pancreatic ductal adenocarcinoma growth by targeting RIG-I. Co-author DOI 10.1016/j.febslet.2014.10.004↗
  13. High expression of delta-like ligand 4 predicts poor prognosis after curative resection for pancreatic cancer. Co-author DOI 10.1245/s10434-011-1968-9↗

Closest collaborators

The 25 strongest of 56 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gang Jin · 12 shared papers, 2012–2025 · strength 1.09
  2. Kailian Zheng · 6 shared papers, 2015–2025 · strength 0.76
  3. Shiwei Guo · 6 shared papers, 2014–2025 · strength 0.76
  4. Suizhi Gao · 4 shared papers, 2021–2025 · strength 0.58
  5. Xiaohan Shi · 4 shared papers, 2021–2025 · strength 0.58
  6. Xiongfei Xu · 3 shared papers, 2023–2025 · strength 0.49
  7. Xiaoyi Yin · 3 shared papers, 2023–2025 · strength 0.49
  8. Meilong Shi · 2 shared papers, 2025 · strength 0.35
  9. Zhuo Shao · 3 shared papers, 2019–2023 · strength 0.32
  10. Guoxiao Zhang · 2 shared papers, 2023–2025 · strength 0.29
  11. Gang Li · 3 shared papers, 2015–2025 · strength 0.28
  12. Ru Gao · 1 shared paper, 2025 · strength 0.27
  13. Zhendong Fu · 1 shared paper, 2025 · strength 0.19
  14. Chenghao Shao · 4 shared papers, 2014–2015 · strength 0.19
  15. Chunming Zhang · 1 shared paper, 2025 · strength 0.16
  16. Yunguang Li · 1 shared paper, 2025 · strength 0.16
  17. Wei Jing · 1 shared paper, 2025 · strength 0.16
  18. Dong Gao · 1 shared paper, 2025 · strength 0.16
  19. An‐An Liu · 3 shared papers, 2014–2015 · strength 0.14
  20. Weiping Ji · 2 shared papers, 2014–2019 · strength 0.14
  21. Lingyu Zhu · 1 shared paper, 2023 · strength 0.13
  22. Bo Li · 1 shared paper, 2023 · strength 0.13
  23. Shuo Shen · 1 shared paper, 2023 · strength 0.13
  24. Jian Wang · 1 shared paper, 2023 · strength 0.13
  25. Peng Cheng · 1 shared paper, 2023 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.